Avadel pharmaceuticals announces fda approval of lumryz™ (sodium oxybate) extended-release oral suspension (ciii) for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy

-- lumryz is the only fda-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy—

AVDL Ratings Summary

AVDL Quant Ranking